[go: up one dir, main page]

MX2020004094A - Metodos para administrar inmunoterapia con receptores de antigeno quimerico. - Google Patents

Metodos para administrar inmunoterapia con receptores de antigeno quimerico.

Info

Publication number
MX2020004094A
MX2020004094A MX2020004094A MX2020004094A MX2020004094A MX 2020004094 A MX2020004094 A MX 2020004094A MX 2020004094 A MX2020004094 A MX 2020004094A MX 2020004094 A MX2020004094 A MX 2020004094A MX 2020004094 A MX2020004094 A MX 2020004094A
Authority
MX
Mexico
Prior art keywords
methods
cell
cell lymphoma
chimeric antigen
antigen receptors
Prior art date
Application number
MX2020004094A
Other languages
English (en)
Other versions
MX421741B (es
Inventor
Jeffrey S Wiezorek
Original Assignee
Kite Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kite Pharma Inc filed Critical Kite Pharma Inc
Publication of MX2020004094A publication Critical patent/MX2020004094A/es
Publication of MX421741B publication Critical patent/MX421741B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación proporciona células que comprenden inmunoterapia con células T autólogas modificadas genéticamente dirigidas a CD19 para el tratamiento de, por ejemplo, linfoma de células B grandes recidivante o refractario después de dos o más líneas de terapia sistémica, incluyendo linfoma difuso de células B grandes (LDCBG) no especificado de otra manera, linfoma mediastínico primario de células B grandes, linfoma de células B de alto grado y LDCBG derivado de linfoma folicular. Algunos aspectos de la divulgación se refieren a métodos de tratamiento y monitoreo después de la infusión de la terapia con células T proporcionada en la presente.
MX2020004094A 2017-10-18 2018-10-18 Inmunoterapia con receptores de antígeno quimérico y uso de la misma MX421741B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574159P 2017-10-18 2017-10-18
PCT/US2018/056467 WO2019079564A1 (en) 2017-10-18 2018-10-18 METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY

Publications (2)

Publication Number Publication Date
MX2020004094A true MX2020004094A (es) 2020-07-21
MX421741B MX421741B (es) 2025-03-14

Family

ID=64477267

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004094A MX421741B (es) 2017-10-18 2018-10-18 Inmunoterapia con receptores de antígeno quimérico y uso de la misma
MX2025002021A MX2025002021A (es) 2017-10-18 2020-07-13 Inmunoterapia con receptores de antigeno quimerico y uso de la misma

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025002021A MX2025002021A (es) 2017-10-18 2020-07-13 Inmunoterapia con receptores de antigeno quimerico y uso de la misma

Country Status (15)

Country Link
US (2) US20190151361A1 (es)
EP (1) EP3697500A1 (es)
JP (2) JP2021500333A (es)
KR (3) KR20230011487A (es)
CN (1) CN111479613A (es)
AR (1) AR113777A1 (es)
AU (4) AU2018351046A1 (es)
BR (1) BR112020007493A2 (es)
CA (1) CA3084470A1 (es)
CO (1) CO2020004804A2 (es)
IL (2) IL273629B2 (es)
MX (2) MX421741B (es)
SG (1) SG11202003380TA (es)
TW (2) TWI866888B (es)
WO (1) WO2019079564A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190336533A1 (en) 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
JP7386796B2 (ja) 2017-11-14 2023-11-27 グリーン クロス ラボ セル コーポレーション 抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US20200003758A1 (en) 2018-06-01 2020-01-02 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
AU2019347710B2 (en) * 2018-09-24 2025-05-08 Amgen Inc. Interventional dosing systems and methods
US11793834B2 (en) 2018-12-12 2023-10-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
EP3962535A1 (en) * 2019-04-30 2022-03-09 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
CN118593691A (zh) * 2019-05-03 2024-09-06 凯德药业股份有限公司 施用嵌合抗原受体免疫疗法的方法
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
AU2020385062A1 (en) * 2019-11-13 2022-05-19 Crispr Therapeutics Ag CD70+ solid tumor therapy using genetically engineered T cells targeting CD70
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2024092227A1 (en) 2022-10-28 2024-05-02 Kite Pharma, Inc. Factors for optimizing immunotherapy
EP4608416A1 (en) * 2022-10-28 2025-09-03 Kite Pharma, Inc. Expedited administration of engineered lymphocytes
KR20240119436A (ko) 2023-01-30 2024-08-06 에이치엘만도 주식회사 스티어링 휠의 핸즈 온/오프 감지 장치 및 방법
US20240309428A1 (en) 2023-03-17 2024-09-19 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025188561A1 (en) 2024-03-04 2025-09-12 Kite Pharma, Inc. Predictive markers for immunotherapy

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX2013008376A (es) 2011-01-18 2013-08-12 Univ Pennsylvania Composiciones y metodos para el tratamiento de cancer.
SG193591A1 (en) 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
MX2014003176A (es) 2011-09-16 2015-08-05 Univ Pennsylvania Celulas t diseñadas mediante arn para el tratamiento de cancer.
ES2859522T3 (es) * 2012-07-13 2021-10-04 Univ Pennsylvania Control de la toxicidad para la actividad antitumoral de CAR
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PL3102609T3 (pl) * 2014-02-04 2025-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sposoby wytwarzania autologicznych komórek t przydatnych w leczeniu nowotworów złośliwych b-komórkowych i innych nowotworów oraz ich kompozycje
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法

Also Published As

Publication number Publication date
CO2020004804A2 (es) 2020-05-05
TW201927315A (zh) 2019-07-16
IL273629A (en) 2020-05-31
BR112020007493A2 (pt) 2020-10-27
AU2023202308A1 (en) 2023-05-11
US20190151361A1 (en) 2019-05-23
MX421741B (es) 2025-03-14
AU2025220739A1 (en) 2025-09-11
JP2023154073A (ja) 2023-10-18
IL320802A (en) 2025-07-01
KR20200071753A (ko) 2020-06-19
WO2019079564A1 (en) 2019-04-25
EP3697500A1 (en) 2020-08-26
AU2023202308B2 (en) 2025-05-22
MX2025002021A (es) 2025-04-02
KR20230011487A (ko) 2023-01-20
US20240058381A1 (en) 2024-02-22
JP2021500333A (ja) 2021-01-07
IL273629B2 (en) 2025-10-01
IL273629B1 (en) 2025-06-01
CA3084470A1 (en) 2019-04-25
AR113777A1 (es) 2020-06-10
AU2018351046A1 (en) 2020-04-30
SG11202003380TA (en) 2020-05-28
AU2021282551B2 (en) 2023-01-19
KR20250054837A (ko) 2025-04-23
CN111479613A (zh) 2020-07-31
TWI866888B (zh) 2024-12-21
AU2021282551A1 (en) 2022-01-06
TW202510896A (zh) 2025-03-16
NZ763357A (en) 2023-10-27

Similar Documents

Publication Publication Date Title
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
ZA202206078B (en) Anti-cd3 antibodies and methods of use
CO2019000946A2 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos
EA201790624A1 (ru) Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
SG10201903912XA (en) Delivery of biomolecules to immune cells
MX2020007543A (es) Metodos para administrar inmunoterapia de receptor de antigeno quimerico en combinacion con agonista 4-1bb.
MX2021013394A (es) Métodos para administrar inmunoterapia con receptor de antígeno quimérico.
MX2017015046A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
MX2019014008A (es) Composiciones y usos para inmunoterapia.
MX2022008338A (es) Inmunoterapia antitumoral combinada.
CL2018002828A1 (es) Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores.
MX2017014193A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
SA517381666B1 (ar) B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا
MX2018010445A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
MX381276B (es) Moduladores de linfocitos t reguladores multivalentes.
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2016010856A (es) Metodo.
MX376663B (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
GT201600171A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblástica aguda
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
TR201903074T4 (tr) Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv